In a previous trial, patients with RSK2-high cancers had a significantly greater benefit from treatment with PMD-026 than those with RSK2-low cancers.
The Phase II portion is seeking to establish safety and efficacy of the company’s HER2 breast cancer therapy in combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results